ClinicalTrials.gg
CompletedNCT05348694OsteoPrePUpdated Nov 10, 2026

OsteoPreP: Food Supplements for Postmenopausal Bone Health

A Phase 4 interventional study of Pendulum WBF-038 and Pendulum Placebo in Postmenopausal Osteopenia, Bone Loss, Age Related and Age-Related Sarcopenia, sponsored by Australian Catholic University. Completed at 1 site in Australia. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Australian Catholic University · Phase 4, Interventional, and Prevention

How we know

Updated Nov 10, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Osteoporosis with a site in Australia — 1 open to participants now, 1 under way, none of them phase 3. Osteoporosis · Australia.

Enrollment
18th of 32
160 · median 188
Started
2022
with 1 other
Phase 4
4 of 33
none open now
Registered
32nd of 33
by date
Lead sponsor
1 of 33
Australian Catholic University

Among the 33 studies in Osteoporosis with a site in Australia, this one is the 18th largest by enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 32nd registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

1 of the 33 studies in Osteoporosis with a site in Australia is open now. Recruiting first, the newest first:

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 40 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Osteoporosis with a site in Australia, or all of them as a file.
02

Study summary

To evaluate the effect of 12 months of supplementation with a probiotic (probiotic plus prebiotic; 2 capsules per day) on relative change (%) in total volumetric bone density (measured using high resolution peripheral quantitative computed tomography [HR-pQCT]) of the distal tibia.

Read the detailed description

It is well established that bone loss occurs throughout life after the attainment of peak bone mass which is usually reached by the end of the second decade of life. During the first 5-8 years following menopause, women experience an accelerated bone loss, which is then followed by a slower phase of decline in bone mineral density (BMD). As over 40% of all women in Australia will suffer an osteoporotic (fragility) fracture in their lifetime, investigating interventions that can prevent bone loss in postmenopausal women is a critical focus. The menopausal transition is also associated with an increased risk of cardiovascular disease, diabetes, and cognitive decline. These conditions and their treatments can also affect bone health.

Previous research has indicated a potential link between the gut microbiome and bone health. Animal studies indicate that interventions affecting the gut microbiome may be successful in reducing bone loss, but human data is limited. Moreover, there is an emerging body of evidence linking the gut microbiome to cognitive, muscle and cardiometabolic function. Such studies indicate that probiotics (healthy gut bacteria) or prebiotics (food for healthy bacteria, e.g. fibre) can increase the amount of short chain fatty acids - such as butyrate -produced by the bacteria in the gut which may mediate the beneficial effects of improving gut health.

The proposed study is a double-blind, placebo-controlled randomised trial, which will investigate whether consuming a probiotic supplement containing inulin (a prebiotic soluble fibre) twice daily for 12 months will improve bone health in postmenopausal women. In addition, secondary outcomes will measure the effect of the intervention on immune system modulation and cognition as well as musculoskeletal and metabolic function as potential mediators.

One hundred and sixty postmenopausal women residing in Melbourne (Victoria, Australia) who are at least one year from their final menses will be recruited from the community via a mail out, advertisements in newspapers, social media, flyers as well as a landing page on an ACU managed website. The investigators have also applied for assisted mail outs through Services Australia for recruitment purposes. Services Australia is able to extract names and addresses of some target study demographics (females living in Melbourne aged between 40 and 65) from the Medicare database and mail them the study details on our behalf. Those wishing to participate will undergo a series of baseline assessments inclusive of bone mineral density scans, blood and stool sampling and physical activity and lifestyle questionnaires. They will then be randomised, in a blinded fashion, to consume one of the following two supplements:

  • Placebo control group (n = 80): Placebo capsule - 2 capsules per day
  • Probiotics group (n=80): Probiotic capsule - 2 capsules per day

Study outcomes will be measured at baseline, 6 months, and 12 months. In addition, participants will be contacted via the telephone and email at three-month and nine-month timepoints to report any adverse responses to the supplementation. At the 12-month time point, participants will cease supplementation and immediately (within 24 hours) attend a post intervention assessment and will complete identical assessment measures to those they did at baseline. Finally, at 2 weeks post supplementation cessation participants will be asked to attend an appointment to provide a final stool sample.

If it can be confirmed that long term consumption of a probiotic supplement can have beneficial effects on bone health, muscle health, and metabolic health in postmenopausal women, this intervention could be recommended in the prevention of osteoporosis and associated musculoskeletal and metabolic conditions.

03

Conditions studied

  • Postmenopausal Osteopenia
  • Bone Loss, Age Related
  • Age-Related Sarcopenia
  • Glucose Metabolism Disorders
  • Age-related Cognitive Decline

Keywords

  • Postmenopausal bone loss
  • Probiotics
  • Volumetric bone mineral density
  • Short-chain fatty acids
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women, 40-65 years old
  • Caucasian (due to significant differences in BMD and bone remodelling between ethnicities)
  • At least one year since final menses
  • Signed
  • Up to date Covid 19 vaccination status
  • Able to walk without the use of an aid
  • Stated availability throughout the entire study period
  • Mental capacity to understand and willingness to fulfil all the details of the protocol
  • Residing in Melbourne, Victoria, Australia

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of osteoporosis
  • T-score of -2.5 or less at the femoral neck or lumbar spine (L1-L4) on the DXA scan at screening visit
  • ≥6.5% at screening visit
  • Blood pressure at screening visit of systolic >180 mmHg and/or diastolic >120 mmHg
  • Untreated hyperthyroidism
  • Rheumatoid arthritis
  • Diagnosed with a disease-causing secondary osteoporosis or malabsorption: , inflammatory bowel disease, celiac disease, type 1/type 2 diabetes, or chronic liver disease
  • Bariatric surgery
  • Recently diagnosed (within the last 5 years)
  • Current or recent oral use (any dose within the last 3 months, or 5mg of Prednisolone (or equivalent) or a higher daily dose for 14 days or more 3-12 months prior to screening)
  • Use of antiresorptive therapy, including systemic hormone replacement therapy, bisphosphonates, strontium ranelate (current or during the last 3 years)
  • Use of teriparatide (current or during the last 3 years)
  • Participation in other clinical intervention trials
  • Antibiotics treatment 2 months prior to inclusion
  • Unwilling to cease taking other probiotic or prebiotic supplements (current use)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Pendulum WBF-038

    Pendulum WBF-038, a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.

    Dietary Supplement: Pendulum WBF-038

  • Placebo comparator
    Pendulum Placebo

    Pendulum Placebo containing Magnesium stearate - 1 capsule with the morning meal and 1 capsule with the evening meal for 12 months.

    Dietary Supplement: Pendulum Placebo

Interventions

  • Dietary supplementPendulum WBF-038

    All bacteria contained in Pendulum WBF-038 are commensal organisms that have been repeatedly documented to inhabit the human gastrointestinal tract under normal circumstances. Pendulum's WBF-038 is a proprietary formulation of the following strains: Akkermansia muciniphila, Clostridium butyricum, Clostridium beijerinckii, Anaerobutyricum hallii, Bifidobacterium infantis, plus chicory inulin and magnesium stearate. The organisms were grown under controlled conditions consistent with Good Manufacturing Practices (GMP) and employ no animal-derived products. All ingredients utilized during manufacturing were food grade and qualified as generally recognized as safe (GRAS). The product is provided as acid-resistant capsules in bottles that are to be stored refrigerated at 4℃.

  • Dietary supplementPendulum Placebo

    Pendulum placebo capsules containing magnesium stearate

06

What researchers measure

Primary outcomes

  1. Total volumetric bone mineral density of the distal tibia

    Percentage change in total volumetric bone density measured using high resolution peripheral quantitative computed tomography (HR-pQCT) of the distal tibia.

    Time frame: 12 months

Secondary outcomes

  1. Bone mineral density of the lumbar spine

    Relative change in lumbar spine (L1-L4) bone mineral density (BMD) measured using dual energy X-ray absorptiometry (DXA)

    Time frame: 12 months

  2. Bone mineral density of the hip

    Relative change in total hip BMD measured using DXA

    Time frame: 12 months

  3. Tibia and radius trabecular bone volume

    Relative change in tibia and radius trabecular bone volume fraction measured using HR-pQCT

    Time frame: 12 months

  4. Tibia and radius cortical area

    Relative change in tibia and radius cortical area measured using HR-pQCT

    Time frame: 12 months

  5. Tibia and radius cortical volumetric bone mineral density

    Relative change in tibia and radius cortical volumetric BMD measured using HR-pQCT

    Time frame: 12 months

  6. Total volumetric bone mineral density of the distal radius

    Relative change in total volumetric BMD of the distal radius measured using HRpQCT

    Time frame: 12 months

  7. Serum C-terminal cross-linking telopeptide of type I collagen (ßCTX-I) - bone turnover marker

    Relative change in ßCTX-I in serum

    Time frame: 6 months and 12 months

  8. Serum procollagen type 1 N-terminal propeptide (P1NP) - bone turnover marker

    Relative change in P1NP levels in serum

    Time frame: 6 months and 12 months

  9. Serum osteocalcin (OC) - bone turnover marker

    Relative change in OC in serum

    Time frame: 6 months and 12 months

  10. Short-chain fatty acids (SCFAs)

    Relative change in SCFA levels (including butyrate) in stool

    Time frame: 6 months, 12 months, and 2 weeks post intervention

  11. 16s rRNA genetic sequencing of the gut microbiota

    Relative change in species-level gut microbiota composition in stool using 16s rRNA sequencing

    Time frame: 6 months, 12 months, and 2 weeks post intervention

  12. Fasting blood glucose

    Relative change in fasted blood glucose levels in circulating blood

    Time frame: 6 months and 12 months

  13. Glycated haemoglobin (HbA1c)

    Relative change in HbA1c levels in circulating blood

    Time frame: 6 months and 12 months

  14. Lower leg muscle area

    Relative change in lower leg muscle area measured using HR-pQCT

    Time frame: 12 months

  15. Lean body mass

    Relative change in appendicular lean body mass measured using DXA

    Time frame: 12 months

  16. Grip strength

    Relative change in left and right hand grip strength measured using a hand dynamometer

    Time frame: 6 months and 12 months

  17. High-sensitivity C-reactive protein (hs-CRP)

    Relative change in hs-CRP levels in serum

    Time frame: 6 months and 12 months

  18. Regulatory T lymphocytes (Tregs)

    Relative change in circulating number of Tregs in blood

    Time frame: 12 months

  19. Oral glucose tolerance test (OGTT)

    Relative change in oral glucose tolerance in circulating blood

    Time frame: 6 months and 12 months

  20. Muscle tissue glycogen content

    Relative change in muscle tissue glycogen content obtained from a muscle biopsy

    Time frame: 6 months and 12 months

  21. Muscle tissue triglyceride content

    Relative change in muscle tissue triglyceride content obtained from a muscle biopsy

    Time frame: 6 months and 12 months

  22. Muscle tissue type 1 fibre composition

    Relative change in muscle tissue type 1 fibre proportion obtained from a muscle biopsy

    Time frame: 6 months and 12 months

  23. Lipocalin2

    Relative change in Lipocalin2 (intestinal inflammation) in stool

    Time frame: 6 months, 12 months, and 2 weeks post intervention

  24. Cogstate One back Test Cognitive performance test

    Relative change in speed of performance and number of errors in the One Back Test using the Cogstate cognitive assessment tool. Lower score = better performance

    Time frame: 6 months and 12 months

  25. Cogstate Groton Maze Learning Test Cognitive performance test

    Relative change in number of errors in the Groton Maze Learning Test using the Cogstate cognitive assessment tool. Lower score = better performance

    Time frame: 6 months and 12 months

  26. Cogstate Continuous Paired Associate Learning Test Cognitive performance test

    Relative change in accuracy of performance and number of errors in the Continuous Paired Associate Learning Test using the Cogstate cognitive assessment tool. Lower score = better performance

    Time frame: 6 months and 12 months

  27. Cogstate Social Emotional Cognition Test Cognitive performance test

    Relative change in accuracy of performance in the Social Emotional Cognition Test using the Cogstate cognitive assessment tool. Higher score = better performance

    Time frame: 6 months and 12 months

  28. Depression, Anxiety and Stress Scale 21

    Relative change in depression, anxiety and stress measured using the Depression Anxiety and Stress Scale 21 (DASS-21) questionnaire. The DASS-21 has a minimum score of 0 and a maximum score of 63 with higher scores indicating a worse outcome.

    Time frame: 6 months and 12 months

  29. Gastrointestinal Symptom Rating Scale

    Relative change in gastrointestinal symptoms measured using the Gastrointestinal Symptom Rating Scale (GSRS) questionnaire. The GSRS has a minimum score of 5 and a maximum score of 45 with higher scores indicating a worse outcome.

    Time frame: 6 months and 12 months

  30. Plasma glucagon-like peptide 1

    Relative change in gut hormone glucagon-like peptide 1 \[GLP-1\] in plasma

    Time frame: 6 months and 12 months

  31. Plasma peptide tyrosine-tyrosine

    Relative change in gut hormone peptide tyrosine-tyrosine \[PYY\] in plasma

    Time frame: 6 months and 12 months

  32. Plasma adiponectin

    Relative change adiponectin in plasma

    Time frame: 6 months and 12 months

  33. EuroQol Five Dimensions Quality of life Medical Outcome Survey

    Relative change in quality of life measured using the EuroQol Five Dimensions (EQ-5D) questionnaire. The EQ-5D has a minimum score of Level 1 and a maximum score of Level 5 with higher levels indicating a worse outcome

    Time frame: 6 months and 12 months

  34. Social Interaction Anxiety Scale

    Relative change in social anxiety measured using the Social Interaction Anxiety Scale (SIAS) questionnaire. The SIAS has a minimum score of 0 and a maximum score of 80 with higher scores indicating a worse outcome.

    Time frame: 6 months and 12 months

  35. The Warwick-Edinburgh Mental Wellbeing Scale

    Relative change in mental wellbeing measured using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS) questionnaire. The WEMWBS has a minimum score of 14 and a maximum score of 70 with higher scores indicating a better outcome.

    Time frame: 6 months and 12 months

  36. Continuous blood glucose level monitoring for 10 days

    Relative change in blood glucose (area under the curve) over 10 days measured using a continuous glucose monitoring device

    Time frame: 6 months and 12 months

  37. Fasting blood insulin

    Relative change in fasted blood insulin levels in circulating blood

    Time frame: 6 months and 12 months

  38. Fat mass

    Relative change in total body fat mass measured using DXA

    Time frame: 12 months

  39. Blood metabolomics

    Relative change in blood metabolites using liquid chromatography-mass spectrometry

    Time frame: 12 months

  40. Office blood pressure

    Relative change in Systolic and Diastolic blood pressure measured using a sphygmomanometer

    Time frame: 6 months and 12 months

  41. The Visual Analogue Scale Pain Intensity

    Relative change in current pain intensity measured using a visual analogue scale (VAS) pain intensity scale. The VAS has a minimum score of 0 and a maximum score of 10 with higher scores indicating a worse outcome.

    Time frame: 6 months and 12 months

  42. Calprotectin

    Relative change in calprotectin (intestinal inflammation) in stool

    Time frame: 6 months, 12 months, and 2 weeks post intervention

  43. Muscle mass

    Relative change in total body muscle mass measured using DXA

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Turbic A, Vandenput L, Gandham A, Lorentzon M. Effects of Synbiotic Supplementation on Bone and Metabolic Health in Caucasian Postmenopausal Women: Rationale and Design of the OsteoPreP Trial. Nutrients. 2024 Dec 6;16(23):4219. doi: 10.3390/nu16234219. PubMed 39683612 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Mar 2024, 22 months.

Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 22 months is below that.

Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2025 → May 2025, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Apr 27, 2022
StartActual
May 1, 2022
Primary completionActual
Mar 28, 2024
CompletionActual
May 5, 2025was Apr 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 10, 2026
Study completion
Apr 2025→May 5, 2025 (actual)
Nov 10, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39683612 ↗
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39683612 ↗
    Study completion Apr 2025→May 5, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05348694
Lead sponsor
Australian Catholic University
Collaborators
Pendulum Therapeutics, Curtin University
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
May 1, 2022
Primary completion
Mar 28, 2024
Completion
May 5, 2025
Last update
Nov 10, 2026

Study contacts

John Hawley, PhD
principal investigator · Australian Catholic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion